Elsevier Inc.

SHERPA: Unknown

People

  1. Usmani
    Usmani
  2. Giralt
    Giralt
  3. Lesokhin
    Lesokhin
  4. Mauro
    Mauro
  5. Landau
    Landau
  6. Hassoun
    Hassoun
  7. Korde
    Korde
  8. Hultcrantz
    Hultcrantz
  9. Chung
    Chung
  10. Mailankody
    Mailankody

Groups

  1. Hematologic Malignancies, Division of (298)
  2. Department of Medicine (295)
  3. Center for Hematologic Malignancies (277)
  4. Adult Leukemia (113)
  5. Myeloma (77)
  6. Hematologic Malignancies Research (71)
  7. Survivorship Research (71)
  8. Bone Marrow Transplant (64)
  9. Lymphoma (61)
  10. Sloan Kettering Institute Postdocs (51)
Search Within
  1. "Clinical Lymphoma, Myeloma and Leukemia"
Formats
  1. Meeting Abstract (271)
  2. Journal Article (69)
  3. Review (7)
  4. Conference Paper (1)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (298)
  2. Department of Medicine (295)
  3. Center for Hematologic Malignancies (277)
  4. Adult Leukemia (113)
  5. Myeloma (77)
  6. Hematologic Malignancies Research (71)

More Groups

People
  1. Saad Usmani (56)
  2. Sergio Giralt (48)
  3. Alexander Lesokhin (44)
  4. Michael Mauro (43)
  5. Heather Landau (42)
  6. Hani Hassoun (40)

More People

Years
  1. 2024 (1)
  2. 2023 (79)
  3. 2022 (64)
  4. 2021 (40)
  5. 2020 (29)
  6. 2019 (38)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (350)

Results (350)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line treatment with subcutaneous epcoritamab plus R-CHOP in patients with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • L-MIND: Safety and efficacy of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma on treatment for at least 2 years
    Meeting Abstract

    Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Carbó, E. P.; Abrisqueta, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Subgroup analysis in RE-MIND2: An observational, retrospective cohort study of tafasitamab + lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Nowakowski, G.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P.; Kim, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin Lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Straus, D.; Radford, J.; Connors, J.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J.; Advani, R.; Hutchings, M.; Evens, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-naive or with suboptimal response to ruxolitinib - Preliminary data from the MANIFEST study
    Meeting Abstract

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F.; Devos, T.; Passamonti, F.; Hobbs, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of pelabresib (CPI-0610) in combination with ruxolitinib vs. JAK inhibitor monotherapy in patients with intermediate or high-risk myelofibrosis
    Meeting Abstract

    Gupta, V.; Mascarenhas, J.; Kremyanskaya, M.; Rampal, R. K.; Talpaz, M.; Kiladjian, J. J.; Vannucchi, A.; Verstovsek, S.; Colak, G.; Dey, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with low versus higher baseline platelet counts: A subgroup analysis of data from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • ASC2ESCALATE trial in progress: A phase 2 single-arm dose escalation study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CMLCP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Sasaki, K.; Mauro, M. J.; Levy, M. Y.; Atallah, E. L.; Koller, P.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • AIM4CML Trial in progress: A phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without the T315I mutation
    Meeting Abstract

    Levy, M. Y.; Mauro, M. J.; Issa, G. C.; Andorsky, D.; Tomassetti, S.; Broun, E. R.; Maegawa, R.; Deininger, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save